Furthermore, they found that this higher susceptibility contributes to audiogenic seizures in the Fmr1 knock-out mouse, stating the need to target the ERK1/2 pathway and signaling pathway converging to ERK1/2 to develop future therapies for the FXS [119]. The gene discussed is MAPK3; the disease is fragile X syndrome.